{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:25:45Z","timestamp":1785320745238,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nonalcoholic fatty liver disease (NAFLD) and gallstone disease (GSD) often coexist in the general population owing to shared risk factors. This study explored the relationship between NAFLD and GSD in patients with type 2 diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective cross-sectional analysis of 4325 patients with type 2 diabetes. GSD and NAFLD were confirmed using ultrasonography. GSD was defined as either asymptomatic gallstones or previous cholecystectomy, and each was analyzed separately.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>There was no significant difference in the prevalence of GSD between patients with and without NAFLD (23.8% vs. 21.2%, <jats:italic>P<\/jats:italic>\u2009=\u20090.15). After case\u2013control matching (1:1) of baseline data such as age, sex, duration of diabetes, and HbA1c between patients with and without NAFLD, there was still no significant difference in the prevalence of GSD (25.5% vs. 23.6%, <jats:italic>P<\/jats:italic>\u2009=\u20090.15). The prevalence of NAFLD in patients with asymptomatic gallstones was lower than that of patients without GSD (38.6% vs. 47.3%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), whereas the prevalence in those who had undergone cholecystectomy was much higher (61.2% vs. 47.3%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The ratio of cholecystectomy to asymptomatic gallstone in patients with or without NAFLD was 1.97 and 0.79, respectively. The rate of cholecystectomy was higher in the patients with NAFLD than in those without NAFLD (15.8% vs. 9.3%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), consistent with the result after case\u2013control matching (17.3% vs. 11.2%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Multivariate logistic regression analysis, after adjusting for numerous potential confounding factors, revealed that GSD (OR\u2009=\u20091.241, 95%CI: 1.036\u20131.488, <jats:italic>P<\/jats:italic>\u2009=\u20090.002) and cholecystectomy (OR\u2009=\u20091.946, 95%CI: 1.546\u20132.445, <jats:italic>P<\/jats:italic> &lt; 0.001) were both strongly associated with NAFLD. However, asymptomatic gallstone (OR\u2009=\u20090.663, 95%CI: 0.513\u20130.856, <jats:italic>P<\/jats:italic>\u2009=\u20090.002) seemed to be negatively correlated with NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The prevalence of GSD was similar in patients with type 2 diabetes with and without NAFLD. The higher proportion of cholecystectomy and lower proportion of asymptomatic gallstones in patients with NAFLD suggests that NAFLD may increase the risk of complications of GSD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-021-00899-z","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T03:02:34Z","timestamp":1637290954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Gallstone disease and nonalcoholic fatty liver disease in patients with type 2 diabetes: a cross-sectional study"],"prefix":"10.1186","volume":"21","author":[{"given":"Ye","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"899_CR1","doi-asserted-by":"publisher","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","volume":"1","author":"EM Brunt","year":"2015","unstructured":"Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:15080.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"899_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","volume":"14","author":"H Tilg","year":"2017","unstructured":"Tilg H, Moschen AR, Roden M. M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32\u201342. https:\/\/doi.org\/10.1038\/nrgastro.2016.147.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"2","key":"899_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrendo.2017.173","volume":"14","author":"G Targher","year":"2018","unstructured":"Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;14(2):99\u2013114. https:\/\/doi.org\/10.1038\/nrendo.2017.173.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"899_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2337\/dc16-1787","volume":"40","author":"F Bril","year":"2017","unstructured":"Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care. 2017;40(3):419\u201330. https:\/\/doi.org\/10.2337\/dc16-1787.","journal-title":"Diabetes Care"},{"issue":"2","key":"899_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/MOG.0000000000000423","volume":"34","author":"A Di Ciaula","year":"2018","unstructured":"Di Ciaula A, Wang DQ, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Curr Opin Gastroenterol. 2018;34(2):71\u201380. https:\/\/doi.org\/10.1097\/MOG.0000000000000423.","journal-title":"Curr Opin Gastroenterol"},{"issue":"2","key":"899_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/hep.30403","volume":"70","author":"F Wang","year":"2019","unstructured":"Wang F, Wang J, Li Y, Yuan J, Yao P, Wei S, et al. Gallstone disease and type 2 diabetes risk: a Mendelian randomization study. Hepatology. 2019;70(2):610\u201320. https:\/\/doi.org\/10.1002\/hep.30403.","journal-title":"Hepatology."},{"issue":"11","key":"899_CR7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/jcm7110458","volume":"7","author":"Y Chang","year":"2018","unstructured":"Chang Y, Noh YH, Suh BS, Kim Y, Sung E, Jung HS, et al. Bidirectional association between nonalcoholic fatty liver disease and gallstone disease: a cohort study. J Clin Med. 2018;7(11):458. https:\/\/doi.org\/10.3390\/jcm7110458.","journal-title":"J Clin Med"},{"issue":"2","key":"899_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3109\/00365521.2011.643481","volume":"47","author":"T Koller","year":"2012","unstructured":"Koller T, Kollerova J, Hlavaty T, Huorka M, Payer J. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol. 2012;47(2):197\u2013203. https:\/\/doi.org\/10.3109\/00365521.2011.643481.","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"899_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/oxfordjournals.aje.a115007","volume":"128","author":"H Nomura","year":"1988","unstructured":"Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Ikematsu H, Noguchi A, et al. Prevalence of gallstone disease in a general population of Okinawa. Japan Am J Epidemiol. 1988;128(3):598\u2013605. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a115007.","journal-title":"Japan Am J Epidemiol"},{"issue":"6","key":"899_CR10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/ajg.2013.70","volume":"108","author":"CE Ruhl","year":"2013","unstructured":"Ruhl CE, Everhart JE. Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol. 2013;108(6):952\u20138. https:\/\/doi.org\/10.1038\/ajg.2013.70.","journal-title":"Am J Gastroenterol"},{"issue":"20","key":"899_CR11","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.3748\/wjg.v21.i20.6287","volume":"21","author":"MS Kwak","year":"2015","unstructured":"Kwak MS, Kim D, Chung GE, Kim W, Kim YJ, Yoon JH. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol. 2015;21(20):6287\u201395. https:\/\/doi.org\/10.3748\/wjg.v21.i20.6287.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"899_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.5009\/gnl.2014.8.3.313","volume":"8","author":"Y Yilmaz","year":"2014","unstructured":"Yilmaz Y, Ayyildiz T, Akin H, Colak Y, Ozturk O, Senates E, et al. Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease. Gut Liver. 2014;8(3):313\u20137. https:\/\/doi.org\/10.5009\/gnl.2014.8.3.313.","journal-title":"Gut Liver"},{"key":"899_CR13","first-page":"163","volume":"18","author":"F Jian-gao","year":"2010","unstructured":"Jian-gao F, Chinese liver disease association. Chinese Liver Disease Association Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi. 2010;18:163\u20136.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"5","key":"899_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1586\/17474124.2015.1007955","volume":"9","author":"S Ballestri","year":"2015","unstructured":"Ballestri S, Romagnoli D, Nascimbeni F, Francica G, Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol. 2015;9(5):603\u201327. https:\/\/doi.org\/10.1586\/17474124.2015.1007955.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"899_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5152\/tjg.2016.0357","volume":"28","author":"SS Shen","year":"2017","unstructured":"Shen SS, Gong JJ, Wang XW, Chen L, Qin S, Huang LF, et al. Promotional effect of nonalcoholic fatty liver disease on gallstone disease: a systematic review and meta-analysis. Turk J Gastroenterol. 2017;28(1):31\u20139. https:\/\/doi.org\/10.5152\/tjg.2016.0357.","journal-title":"Turk J Gastroenterol"},{"issue":"8","key":"899_CR16","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1007\/s10620-016-4125-2","volume":"61","author":"V Jaruvongvanich","year":"2016","unstructured":"Jaruvongvanich V, Sanguankeo A, Upala S. Significant association between gallstone disease and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Dig Dis Sci. 2016;61(8):2389\u201396. https:\/\/doi.org\/10.1007\/s10620-016-4125-2.","journal-title":"Dig Dis Sci"},{"issue":"8","key":"899_CR17","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/j.1440-1746.2005.03924.x","volume":"20","author":"P Loria","year":"2005","unstructured":"Loria P, Lonardo A, Lombardini S, Carulli L, Verrone A, Ganazzi D, et al. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol. 2005;20(8):1176\u201384. https:\/\/doi.org\/10.1111\/j.1440-1746.2005.03924.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"899_CR18","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s11605-008-0704-7","volume":"12","author":"A Ramos-De la Medina","year":"2008","unstructured":"Ramos-De la Medina A, Remes-Troche JM, Roesch-Dietlen FB, P\u00e9rez-Morales AG, Martinez S, Cid-Juarez S. Routine liver biopsy to screen for nonalcoholic fatty liver disease (NAFLD) during cholecystectomy for gallstone disease: Is it justified. J Gastrointest Surg. 2008;12:2097\u2013102 discussion 2102.","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"899_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3109\/00365521.2014.894119","volume":"49","author":"MH Ahmed","year":"2014","unstructured":"Ahmed MH, Ali A. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first? Scand J Gastroenterol. 2014;49(5):521\u20137. https:\/\/doi.org\/10.3109\/00365521.2014.894119.","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"899_CR20","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nm1785","volume":"14","author":"SB Biddinger","year":"2008","unstructured":"Biddinger SB, Haas JT, Yu BB, Bezy O, Jing E, Zhang W, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med. 2008;14(7):778\u201382. https:\/\/doi.org\/10.1038\/nm1785.","journal-title":"Nat Med"},{"issue":"36","key":"899_CR21","doi-asserted-by":"publisher","first-page":"6571","DOI":"10.3748\/wjg.v23.i36.6571","volume":"23","author":"A Lonardo","year":"2017","unstructured":"Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: evolving paradigms. World J Gastroenterol. 2017;23(36):6571\u201392. https:\/\/doi.org\/10.3748\/wjg.v23.i36.6571.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"899_CR22","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.hpb.2020.07.011","volume":"22","author":"I Rodr\u00edguez-Antonio","year":"2020","unstructured":"Rodr\u00edguez-Antonio I, L\u00f3pez-S\u00e1nchez GN, Garrido-Camacho VY, Uribe M, Ch\u00e1vez-Tapia NC, Nu\u00f1o-L\u00e1mbarri N. Cholecystectomy as a risk factor for non-alcoholic fatty liver disease development. HPB (Oxford). 2020;22(11):1513\u201320. https:\/\/doi.org\/10.1016\/j.hpb.2020.07.011.","journal-title":"HPB (Oxford)"},{"issue":"23","key":"899_CR23","doi-asserted-by":"publisher","first-page":"7277","DOI":"10.3748\/wjg.v20.i23.7277","volume":"20","author":"M Acalovschi","year":"2014","unstructured":"Acalovschi M. Gallstones in patients with liver cirrhosis: incidence, etiology, clinical and therapeutical aspects. World J Gastroenterol. 2014;20(23):7277\u201385. https:\/\/doi.org\/10.3748\/wjg.v20.i23.7277.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"899_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cgh.2016.10.023","volume":"15","author":"A Acosta","year":"2017","unstructured":"Acosta A, Streett S, Kroh MD, Cheskin LJ, Saunders KH, Kurian M, et al. White Paper AGA: POWER - Practice Guide on Obesity and Weight Management, Education, and Resources. Clin Gastroenterol Hepatol. 2017;15(5):631\u2013649.e10.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"40","key":"899_CR25","doi-asserted-by":"publisher","first-page":"14942","DOI":"10.3748\/wjg.v20.i40.14942","volume":"20","author":"L Zhu","year":"2014","unstructured":"Zhu L, Aili A, Zhang C, Saiding A, Abudureyimu K. Prevalence of and risk factors for gallstones in Uighur and Han Chinese. World J Gastroenterol. 2014;20(40):14942\u20139. https:\/\/doi.org\/10.3748\/wjg.v20.i40.14942.","journal-title":"World J Gastroenterol"},{"key":"899_CR26","doi-asserted-by":"publisher","first-page":"e7853","DOI":"10.1097\/MD.0000000000007853","volume":"96","author":"QH Qiao","year":"2017","unstructured":"Qiao QH, Zhu WH, Yu YX, Huang FF, Chen LY. Nonalcoholic fatty liver was associated with asymptomatic gallstones in a Chinese population. Med (Baltim). 2017;96:e7853.","journal-title":"Med (Baltim)"},{"issue":"1","key":"899_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"899_CR28","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s11605-008-0704-7","volume":"12","author":"A Ramos-De la Medina","year":"2008","unstructured":"Ramos-De la Medina A, Remes-Troche JM, Roesch-Dietlen FB, P\u00e9rez-Morales AG, Martinez S, Cid-Juarez S. Routine liver biopsy to screen for nonalcoholic fatty liver disease (NAFLD) during cholecystectomy for gallstone disease: is it justified? J Gastrointest Surg. 2008;12(12):2097\u2013102; discussion 2102. https:\/\/doi.org\/10.1007\/s11605-008-0704-7.","journal-title":"J Gastrointest Surg"},{"issue":"17","key":"899_CR29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1556\/oh.2007.28049","volume":"148","author":"E Fraenkel","year":"2007","unstructured":"Fraenkel E, Tak\u00e1cs R, Hamvas J, Lengyel G, Feh\u00e9r J. A nem alkoholos zs\u00edrm\u00e1j \u00e9s az epek\u00f6vess\u00e9g egy\u00fcttes elofordul\u00e1s\u00e1nak megfigyel\u00e9se [Common occurrence of non-alcoholic fatty liver disease and cholecystolithiasis]. Orv Hetil. 2007;148(17):793\u20138. https:\/\/doi.org\/10.1556\/oh.2007.28049.","journal-title":"Orv Hetil"},{"issue":"2","key":"899_CR30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/hep.30429","volume":"70","author":"RS Khan","year":"2019","unstructured":"Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019;70(2):711\u201324. https:\/\/doi.org\/10.1002\/hep.30429.","journal-title":"Hepatology."},{"issue":"4","key":"899_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12983","volume":"21","author":"VA Cort\u00e9s","year":"2020","unstructured":"Cort\u00e9s VA, Barrera F, Nervi F. Pathophysiological connections between gallstone disease, insulin resistance, and obesity. Obes Rev. 2020;21(4):e12983. https:\/\/doi.org\/10.1111\/obr.12983.","journal-title":"Obes Rev"},{"issue":"9","key":"899_CR32","doi-asserted-by":"publisher","first-page":"ITC65","DOI":"10.7326\/AITC201811060","volume":"169","author":"XJ Wang","year":"2018","unstructured":"Wang XJ, Malhi H. Nonalcoholic fatty liver disease. Ann Intern Med. 2018 Nov 6;169(9):ITC65\u201380. https:\/\/doi.org\/10.7326\/AITC201811060.","journal-title":"Ann Intern Med"},{"issue":"5","key":"899_CR33","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/er.2019-00034","volume":"40","author":"MJ Watt","year":"2019","unstructured":"Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40(5):1367\u201393. https:\/\/doi.org\/10.1210\/er.2019-00034.","journal-title":"Endocr Rev"},{"issue":"7","key":"899_CR34","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908\u201322. https:\/\/doi.org\/10.1038\/s41591-018-0104-9.","journal-title":"Nat Med"},{"issue":"12","key":"899_CR35","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1194\/jlr.RA120000924","volume":"61","author":"G Kakiyama","year":"2020","unstructured":"Kakiyama G, Marques D, Martin R, Takei H, Rodriguez-Agudo D, LaSalle SA, et al. Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition. J Lipid Res. 2020;61(12):1629\u201344. https:\/\/doi.org\/10.1194\/jlr.RA120000924.","journal-title":"J Lipid Res"},{"issue":"5","key":"899_CR36","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","volume":"15","author":"HK Min","year":"2012","unstructured":"Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012;15(5):665\u201374. https:\/\/doi.org\/10.1016\/j.cmet.2012.04.004.","journal-title":"Cell Metab"},{"issue":"8","key":"899_CR37","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrd2619","volume":"7","author":"C Thomas","year":"2008","unstructured":"Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008;7(8):678\u201393. https:\/\/doi.org\/10.1038\/nrd2619.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"899_CR38","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","volume":"67","author":"N Jiao","year":"2018","unstructured":"Jiao N, Baker SS, Chapa-Rodriguez A, Liu W, Nugent CA, Tsompana M, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2018;67(10):1881\u201391. https:\/\/doi.org\/10.1136\/gutjnl-2017-314307.","journal-title":"Gut."},{"issue":"3","key":"899_CR39","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/cphy.c150050","volume":"6","author":"C Housset","year":"2016","unstructured":"Housset C, Chr\u00e9tien Y, Debray D, Chignard N. Functions of the gallbladder. Compr Physiol. 2016;6(3):1549\u201377. https:\/\/doi.org\/10.1002\/cphy.c150050.","journal-title":"Compr Physiol"},{"issue":"12","key":"899_CR40","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.3748\/wjg.v21.i12.3614","volume":"21","author":"HG Wang","year":"2015","unstructured":"Wang HG, Wang LZ, Fu HJ, Shen P, Huang XD, Zhang FM, et al. Cholecystectomy does not significantly increase the risk of fatty liver disease. World J Gastroenterol. 2015;21(12):3614\u20138. https:\/\/doi.org\/10.3748\/wjg.v21.i12.3614.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"899_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/jcm9010015","volume":"9","author":"G Tarantino","year":"2019","unstructured":"Tarantino G, Citro V, Capone D. Nonalcoholic fatty liver disease: a challenge from mechanisms to therapy. J Clin Med. 2019;9(1):15. https:\/\/doi.org\/10.3390\/jcm9010015.","journal-title":"J Clin Med"},{"issue":"2","key":"899_CR42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/MOG.0000000000000416","volume":"34","author":"M Arrese","year":"2018","unstructured":"Arrese M, Cort\u00e9s V, Barrera F, Nervi F. Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy: new insights on a complex relationship. Curr Opin Gastroenterol. 2018;34(2):90\u20136. https:\/\/doi.org\/10.1097\/MOG.0000000000000416.","journal-title":"Curr Opin Gastroenterol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00899-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-021-00899-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00899-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T03:03:07Z","timestamp":1637290987000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00899-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00899-z","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"assertion":[{"value":"10 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Shanghai Sixth People\u2019s Hospital. Due to the retrospective design, informed consent was exempted and all the information did not involve patients privacy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}